The days of one-size fits all drugs are numbered and it is Dundalk-based company Diaceutics that is helping the precision drugs industries gather pace.
Diaceutics‘ CEO Peter Keeling told Siliconrepublic.com that data and AI are now at the heart of pharmaceutical companies’ ability to test the right patients for their new therapies.
‘We have worked on more than 200 therapy programmes to date and by our estimates, we have already helped more than 500,000 patients get better tested’
– PETER KEELING
Each year its technology helps 48,000 cancer patients in the US and EU get biomarker testing and therefore, potentially …read more
Source:: Silicon Republic News